
In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…... [Read More]
In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…... [Read More]
• By Lara C. Pullen, PhD
Recent research reinforces the finding that psoriasis patients have a slightly increased risk of cancer, specifically keratinocyte cancer and lymphomas. However, the study found no association between cancer and the use of biologic treatments in this patient population…... [Read More]
In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…... [Read More]
Research has shown ixekizumab improves pain and the sexual health of patients with genital psoriasis…... [Read More]
Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…... [Read More]
In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…... [Read More]
New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…... [Read More]
• By Mary Choy, PharmD, BCGP, FASHP
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to… [Read More]
In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…... [Read More]
Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…... [Read More]
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.
Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.